Zhitong Finance App News, Changfeng Pharmaceutical (02652) issued an announcement. Recently, the company received a voluntary commitment from Dr. Liang Wenqing, the co-founder, chairman, executive director and CEO of the company, and Dr. Li Li, the co-founder, executive director and chief scientific officer of the company, based on the long-term development prospects and long-term value of the Group. According to the promise, the core management has voluntarily promised to extend the ban on company shares directly or indirectly beneficially owned by it for a further six months after the expiration of the original ban period. The sales ban will be extended from October 8, 2026 to April 7, 2027 (including the first and last two days).
Related shares refer to: (1) 156.774 million H shares and 10.4516 million unlisted shares held by Dr. Liang Wenqing through the Suzhou Lingtou Investment Management Company (limited partnership) controlled by him; (2) 14.3787 million H shares and 9.585 million unlisted shares held by Dr. Li through the Suzhou Meizhongrui Investment Management Company (limited partnership) controlled by him; and (3) Dr. Liang Wenqing and Dr. Li Li, a total of 673,300 shares of interest in the company's employee incentive platform through Suzhou Lingtou and Suzhou Meizhongrui, respectively Shares (these shares are not part of The company's 2024 share incentive plan).
The company believes that the voluntary commitment of core management is based on their confidence in the Group's long-term development strategy, business prospects and ability to create sustainable value, and reflects their commitment to maintain the long-term interests of the company and all shareholders. Commitments are made voluntarily and free of charge by core management.